Premium
Differentiation therapy in acute promyelocytic leukemia: European experience
Author(s) -
Degos Laurent
Publication year - 1997
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/(sici)1097-4652(199711)173:2<285::aid-jcp37>3.0.co;2-c
Subject(s) - acute promyelocytic leukemia , myeloid leukemia , retinoic acid , promyelocytic leukemia protein , chromosomal translocation , fusion gene , leukemia , cancer research , myeloid , biology , immunology , genetic enhancement , in vivo , medicine , gene , genetics
Acute promyelocytic leukemia (APL) is a subset of acute myeloid leukemia characterized by the morphology of the blast cells (M3 type in the FAB nomenclature), and a specific t(15; 17) translocation. APL was further characterized by a specific sensitivity to all‐trans retinoic acid's differentiation effect and the production of a fusion gene altering the gene of RARα and a gene called PML. In vivo differentiation therapy with retinoids in APL patients reduces the risk of relapse and increases the chance of long‐term survival. J. Cell. Physiol. 173:285–287, 1997. © 1997 Wiley‐Liss, Inc.